$IMUN News letter. IMUN offers a new modality

$IMUN News letter.

IMUN offers a new modality for cancer treatment, which holds great promise for becoming a curative therapy with minimal toxicity that works together with or replaces current treatment methods. 

The human immune system is capable of seeking out and destroying cancers cells wherever they reside in the body. Harnessing the power of the immune system holds the greatest potential for winning the battle against cancer.

IMUN 's concept is called the  Mirror Effect™ In the  Mirror Effect™ T-cells from a normal donor are infused into a patient and instead of these foreign cells mediating the  GVT effect , these cells instead stimulate the patient’s own immune system to attack the tumor. 

This effect is known as the  host-vs-tumor (HVT) effect and it is the mirror image of the  GVT effect . 

The patient’s immune system is alerted by the infusion of foreign cells and raises up to reject the foreign cells, an effect known as  host-vs-graft (HVG) . 

The  HVG effect is the mirror image of the  GVH effect . However, unlike the  GVH effect the  HVG effect is not toxic to a patient.

The reason that the  GVT effect is such a powerful immune mechanism for curing cancers is that the interaction between the host and donor creates the release of an array of inflammatory cytokines that signal the body of an imminent danger. 

These danger signals shut down the ability of the tumor to avoid an immune attack and enable immune-mediated killing of tumors disseminated throughout the body. 

The  Mirror Effect™ creates these same danger signals in the context of a rejection response to a foreign cell infusion  (HVG) rather than as an attack against normal tissues  (GVH) .  

Thus the  Mirror Effect™ has the potential to cause a proven curative anti-tumor effect of  BMT without the extremely toxic side-effects. This represents a new concept in the treatment of cancer.

Protocols are being developed for patients with the following indications:

IMUN currently has 2 products  Allostim &  Allovax .

IMUN is establishing potential partnerships for developments and commercialization of its immunotherapy products:

• AlloStimTM
  Phase I/II - Refractory chronic lymphocytic leukemia
  Phase I/II - Bladder cancer
  Phase I/II - HIV/AIDS
  
  


• AlloVaxTM
  Phase I/II – Recurrent glioblastoma Brain cancer
  Phase I/II – Child leukemia Melanoma
  Phase I/II – Head & Neck cancer

DEVELOPMENT PARTNERS INCLUDE:

• University of Colorado


• Mayo Clinic


• University of Arizona


• University of California
  
  

Make sure you place IMUN on your screen tomorrow morning & stay tuned for further updates on this company.